Abbreviations: allo-HCT = allogeneic hematopoietic cell transplantation; ATG = anti-thymocyte globin; ATL = adult T cell leukemia/lymphoma; MMF = mycophenolate mofetil; MOG = mogamulizumab; PD = progressive disease; PTCY = post-transplant cyclophosphamide; SD = stable disease.
Adult T-cell leukemia/lymphoma (ATLL) is a peripheral T-cell neoplasm that is associated with human T-cell leukemia virus type I. 1 Combination chemotherapies (such as mLSG15) against aggressive ATLL have been developed. 2, 3 However, the prognosis is extremely poor and the median survival of patients with aggressive ATLL is still~1 year with conventional chemotherapy. 3 Mogamulizumab (anti-C-C chemokine receptor type 4 (CCR4) monoclonal antibody; MOG) was recently approved as a treatment for ATLL in Japan. Previous phase I and phase II studies of MOG monotherapy for aggressive ATLL showed that MOG was safe and effective in ATLL patients, even though long-term outcomes are unclear. 4, 5 CCR4, a target of MOG, is highly expressed on regulatory T cells (Tregs), which is a pivotal player in the reconstitution of immune tolerance after allogeneic hematopoietic cell transplantation (allo-HCT). 6, 7 Considering that Tregs are significantly depleted in vivo for several months after the administration of MOG (half-life 16-18 days), an important question is reasonably raised whether pretransplant administration of MOG may potentially exacerbate acute GVHD in ATLL patients.
To address this issue, we retrospectively analyzed the transplant outcomes of 91 patients with ATLL who underwent their first allo-HCT between January 2001 and July 2014 at the National Cancer Center Hospital, Tokyo, Japan. Acute and chronic GVHD were diagnosed and graded according to standard criteria. We used Fisher's exact test to compare categorical covariates and the Mann-Whitney U-test to compare continuous covariates. OS was estimated by the Kaplan-Meier method, and differences between groups were evaluated by the log-rank test. Relapse/progression and non-relapse mortality (NRM) were considered as competing risk events for each other. In terms of the incidence of GVHD, relapse and NRM before GVHD were considered as competing risk events for each other. The cumulative incidences of relapse/ progression, NRM and GVHD were estimated by the cumulative incidence function, and differences between groups were evaluated by the Gray test. All statistical analyses were performed with EZR (Saitama Medical Center, Jichi Medical University).
Eleven patients received MOG before allo-HCT. The median time from the last MOG administration to allo-HCT was 46 days (range 17-198 days). The interval between MOG and allo-HCT was 43 half-lives (454 days) in four patients, 2-3 half-lives (36-54 days) in three patients and o 2 half-lives ( o36 days) in four patients. The median total dose of MOG was 5 mg/kg (range 1-8 mg/kg). There was no significant difference in the number of prior chemotherapy regimens excluding MOG ( Table 1 ). The median follow-up period among all survivors was 1703 days after allo-HCT (range 100-4394 days), and the MOG group had a shorter follow-up period (median 249 days; range 101-284 days). More patients received tacrolimus-based GVHD prophylaxis in the MOG group than in the non-MOG group (91 vs 55%, P = 0.025). There was no significant difference in other patient-and transplant-related characteristics (Table 1) . The cumulative incidence of grade II-IV acute GVHD at day100 after allo-HCT in the MOG group was significantly higher than that in the non-MOG group (MOG: 81.8% vs non-MOG: 41.3%, P = 0.002; Figure 1a) . The cumulative incidence of grade III-IV acute GVHD at day100 after allo-HCT in the MOG group tended to be higher than that in the non-MOG group (MOG: 36.4% vs non-MOG: 16.3%, P = 0.113; Figure 1b ). There was no significant difference between the MOG and the non-MOG groups with regard to the incidence of chronic GVHD at 6 months after allo-HCT (MOG: 21.2% vs non-MOG: 31.7%, P = 0.451; Figure 1c ).
The cumulative incidences of NRM at 6 months after allo-HCT were 58.2% in the MOG group and 12.7% in the non-MOG group (Figure 1d ). In the MOG group, the main causes of NRM included infection after severe acute GVHD (n = 3), graft failure (n = 2) and multiple organ failure (n = 1). The probabilities of OS at 6 months after allo-HCT were 31.8% in the MOG group and 77.1% in the non-MOG group (Figure 1e) . Patients in the MOG group had significantly worse outcomes than those in the non-MOG group (NRM, P = 0.001; OS, P = 0.005). Despite the small sample size and short observation period, our data suggested that the administration of MOG before allo-HCT could increase the risks of acute GVHD, NRM and overall mortality. This is the first study to assess the clinical impact of MOG administration, which depletes Tregs in vivo for months. The significant increase in acute GVHD supports the theory that Tregs play an important role in the prevention of acute GVHD after allo-HCT, as demonstrated in mouse models. [8] [9] [10] One important limitation of this study is the small sample size and difference in stem cell source, HLA disparity and chemotherapy before allo-HCT, although there was no statistically significant difference between the MOG group and the non-MOG group. Another limitation is a lack of data about concentration of MOG after allo-HCT and data about immune reconstitution including Tregs. The correlation between the concentration of MOG and recovery of Treg should be determined in future trials.
We can expect that more patients will receive MOG and subsequently undergo allo-HCT, as MOG is approved not only for the rare disease ATLL but also for other T-cell lymphomas expressing CCR4. Thus, it is of critical importance to determine the appropriate management of acute GVHD, including prophylaxis and treatment, in patients who receive MOG before allo-HCT.
In conclusion, despite the small sample size, our study suggested that the use of MOG before allo-HCT significantly worsened the clinical outcome, mainly due to an increased risk of acute GVHD. A larger study is warranted to confirm our findings. However, at present, it seems reasonable to pay careful attention to the use of MOG for patients with ATLL who are eligible for allo-HSCT. If patients with ATLL who received MOG undergo allo-HCT, intensification of GVHD prophylaxis should be considered.
